0	10	Lymphocyte	Lymphocyte	NNP
11	25	glucocorticoid	glucocorticoid	NN
26	34	receptor	receptor	NN
34	35	:	:	:
36	45	predictor	predictor	NN
46	48	of	of	IN
49	59	sertraline	sertraline	NN
60	68	response	response	NN
69	71	in	in	IN
72	82	adolescent	adolescent	JJ
83	88	major	major	JJ
89	99	depressive	depressive	JJ
100	108	disorder	disorder	NN
109	110	(	(	(
110	113	MDD	MDD	NNP
113	114	)	)	)
114	115	.	.	.

117	122	Major	major	JJ
123	133	depressive	depressive	JJ
134	142	disorder	disorder	NN
143	144	(	(	(
144	147	MDD	MDD	NNP
147	148	)	)	)
149	151	in	in	IN
152	163	adolescents	adolescent	NNS
164	176	demonstrates	demonstrate	VBZ
177	187	resistance	resistance	NN
188	190	to	to	TO
191	200	tricyclic	tricyclic	JJ
201	216	antidepressants	antidepressant	NNS
217	220	and	and	CC
221	228	absence	absence	NN
229	231	of	of	IN
232	249	hypercortisolemia	hypercortisolemia	NN
249	250	.	.	.

251	254	The	the	DT
255	263	efficacy	efficacy	NN
264	266	of	of	IN
267	276	serotonin	serotonin	NN
277	285	reuptake	reuptake	NN
286	296	inhibitors	inhibitor	NNS
297	298	(	(	(
298	302	SRIs	SRI	NNP
302	303	)	)	)
304	306	is	be	VBZ
307	316	uncertain	uncertain	JJ
316	317	,	,	,
318	321	and	and	CC
322	330	response	response	NN
331	341	predictors	predictor	NNS
342	345	are	be	VBP
346	357	unavailable	unavailable	JJ
357	358	.	.	.

359	367	Abnormal	abnormal	JJ
368	372	fast	fast	JJ
373	381	feedback	feedback	NN
382	385	and	and	CC
386	394	negative	negative	JJ
395	403	feedback	feedback	NN
404	406	of	of	IN
407	410	the	the	DT
411	441	hypothalamic-pituitary-adrenal	hypothalamic-pituitary-adrenal	JJ
442	446	axis	axis	NN
447	457	implicates	implicate	VBZ
458	459	a	a	DT
460	468	dampened	dampened	JJ
469	487	limbic-hippocampal	limbic-hippocampal	JJ
488	502	glucocorticoid	glucocorticoid	NN
503	507	type	type	NN
508	510	II	ii	CD
511	519	receptor	receptor	NN
520	521	(	(	(
521	525	GCII	GCII	NNP
525	526	)	)	)
526	527	.	.	.

528	530	We	we	PRP
531	543	hypothesized	hypothesize	VBD
544	548	that	that	IN
549	559	lymphocyte	lymphocyte	NN
560	564	GCII	GCII	NNP
565	567	is	be	VBZ
568	575	altered	alter	VBN
576	578	in	in	IN
579	589	adolescent	adolescent	JJ
590	593	MDD	MDD	NNP
594	597	and	and	CC
598	603	could	could	MD
604	609	serve	serve	VB
610	612	as	as	IN
613	614	a	a	DT
615	621	marker	marker	NN
622	625	for	for	IN
626	634	response	response	NN
635	637	to	to	TO
638	642	SRIs	sri	NNS
642	643	.	.	.

644	646	In	in	IN
647	649	an	an	DT
650	660	open-label	open-label	JJ
661	666	study	study	NN
666	667	,	,	,
668	679	adolescents	adolescent	NNS
680	681	(	(	(
681	682	n	n	NN
683	684	=	=	SYM
685	687	20	20	CD
687	688	)	)	)
689	696	meeting	meet	VBG
697	706	DSM-III-R	dsm-iii-r	NN
707	715	criteria	criterion	NNS
716	719	for	for	IN
720	723	MDD	MDD	NNP
724	730	showed	show	VBD
731	739	baseline	baseline	NN
740	750	lymphocyte	lymphocyte	NN
751	755	GCII	GCII	NNP
756	761	sites	site	NNS
762	765	per	per	IN
766	770	cell	cell	NN
771	772	(	(	(
772	782	sites/cell	sites/cell	NN
782	783	)	)	)
784	790	values	value	NNS
791	793	of	of	IN
794	797	793	793	CD
798	801	+/-	+/-	SYM
802	805	106	106	CD
806	812	versus	versus	IN
813	818	2,563	2,563	CD
819	822	+/-	+/-	SYM
823	826	499	499	CD
827	828	(	(	(
828	831	+/-	+/-	SYM
832	835	SEM	SEM	NNP
835	836	)	)	)
837	840	for	for	IN
841	848	matched	match	VBN
849	857	controls	control	NNS
858	859	(	(	(
859	860	n	n	NN
861	862	=	=	SYM
863	865	18	18	CD
865	866	)	)	)
867	868	(	(	(
868	869	t	t	NN
870	871	=	=	JJ
872	875	3.5	3.5	CD
875	876	;	;	:
877	879	df	df	NN
880	881	=	=	JJ
882	884	36	36	CD
884	885	;	;	:
886	887	p	p	NN
888	889	<	<	JJR
890	894	.001	.001	CD
894	895	)	)	)
895	896	.	.	.

897	901	GCII	GCII	NNP
902	905	was	be	VBD
906	915	bimodally	bimodally	RB
916	927	distributed	distribute	VBN
927	928	,	,	,
929	933	with	with	IN
934	937	SRI	SRI	NNP
938	948	responders	responder	NNS
949	958	differing	differ	VBG
959	963	from	from	IN
964	977	nonresponders	nonresponder	NNS
978	979	(	(	(
979	980	t	t	NN
981	982	=	=	JJ
983	986	3.9	3.9	CD
986	987	;	;	:
988	990	df	df	NN
991	992	=	=	JJ
993	995	14	14	CD
995	996	;	;	:
997	998	p	p	NN
999	1000	<	<	JJR
1001	1005	.001	.001	CD
1005	1006	)	)	)
1006	1007	.	.	.

1008	1012	GCII	GCII	NNP
1013	1023	accurately	accurately	RB
1024	1034	classified	classify	VBD
1035	1037	90	90	CD
1038	1045	percent	percent	NN
1046	1048	of	of	IN
1049	1059	sertraline	sertraline	NN
1060	1070	responders	responder	NNS
1071	1074	and	and	CC
1075	1077	80	80	CD
1078	1085	percent	percent	NN
1086	1088	of	of	IN
1089	1102	nonresponders	nonresponder	NNS
1102	1103	.	.	.

1104	1108	Only	only	RB
1109	1112	SRI	SRI	NNP
1113	1123	responders	responder	NNS
1124	1130	showed	show	VBD
1131	1135	GCII	GCII	NNP
1136	1146	sites/cell	sites/cell	NNS
1147	1158	upregulated	upregulate	VBN
1159	1164	after	after	IN
1165	1166	6	6	CD
1167	1172	weeks	week	NNS
1173	1175	of	of	IN
1176	1185	treatment	treatment	NN
1186	1187	(	(	(
1187	1188	t	t	NN
1189	1190	=	=	JJ
1191	1194	2.1	2.1	CD
1194	1195	,	,	,
1196	1198	df	df	NN
1199	1200	=	=	JJ
1201	1203	10	10	CD
1203	1204	;	;	:
1205	1206	p	p	NN
1207	1208	<	<	JJR
1209	1212	.05	.05	CD
1212	1213	)	)	)
1213	1214	.	.	.